1 EXECUTIVE SUMMARY 15

2 INTRODUCTION 21

• 2.1 KEY TAKE AWAYS 21
• 2.2 REPORT DESCRIPTION 21
• 2.3 MARKETS COVERED 23
• 2.4 STAKEHOLDERS 24
• 2.5 RESEARCH METHODOLOGY 24
  • 2.5.1 MARKET SIZE ESTIMATION 25
  • 2.5.2 MARKET CRACKDOWN AND DATA TRIANGULATION 28
  • 2.5.3 SECONDARY SOURCES 29
  • 2.5.4 PRIMARY SOURCES 30
  • 2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES 30
  • 2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES 31
  • 2.5.7 ASSUMPTIONS 31

3 MARKET ANALYSIS 33

• 3.1 INTRODUCTION 33
• 3.2 MARKET SEGMENTATION 34
• 3.3 FACTORS INFLUENCING MARKET 36
  • 3.3.1 DRIVERS AND OPPORTUNITIES 36
    • 3.3.1.1 Increasing catheterization related procedures 36
    • 3.3.1.2 Preference for minimally-invasive solutions 37
    • 3.3.1.3 Ease in usage and quick hemostatic properties of VCDs 38
    • 3.3.1.4 Increased utilization of transradial arterial access 38
  • 3.3.2 RESTRAINTS AND THREATS 39
    • 3.3.2.1 High price of products 39
    • 3.3.2.2 Complications associated with VCD 39
    • 3.3.2.3 Less adoption of novel technologies in emerging countries 40
    • 3.3.2.4 Reduced reimbursement 40
    • 3.3.2.5 Usage of animal related sources 41
    • 3.3.2.6 Lower revenue potential of VCD 41
• 3.4 PORTER’S FIVE FORCE ANALYSIS 41
  • 3.4.1 THREAT OF NEW ENTRANTS 42
  • 3.4.2 THREAT OF SUBSTITUTES 42
  • 3.4.3 BARGAINING POWER OF SUPPLIERS 44
  • 3.4.4 BARGAINING POWER OF BUYERS 44
  • 3.4.5 COMPETITIVE RIVALRY 44
• 3.5 REGULATORY AFFAIRS 45
  • 3.5.1 U.S. 45
  • 3.5.2 EUROPE 46
  • 3.5.3 INDIA 46
  • 3.5.4 CHINA 47
  • 3.5.5 JAPAN 48
• 3.6 REIMBURSEMENT SCENARIO 49
  • 3.6.1 TRANSCATHETER EMBOLIZATION OR OCCLUSION SERVICES 49
  • 3.6.2 THROMBOLYSIS 51
  • 3.6.3 DIAGNOSTIC CARDIAC CATHETERIZATION 51
  • 3.6.4 INJECTION DIAGNOSTIC CARDIAC CATHETERIZATION 56
• 3.7 UPCOMING TECHNOLOGIES 58
• 3.8 SUPPLY CHAIN ANALYSIS 58
• 3.9 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 60
• 3.10 PATENT TRENDS 62

4 VASCULAR CLOSURE DEVICES GLOBAL MARKET, BY TYPE 64

• 4.1 INTRODUCTION 64
• 4.2 ACTIVE APPROXIMATORS 66
  • 4.2.1 CLIPS 70
  • 4.2.2 SUTURE MEDIATED DEVICES 72
  • 4.2.3 PLUGS 73
    • 4.2.3.1 Collagen based 75
    • 4.2.3.2 Polymer based 76
    • 4.2.3.3 FISH 78
• 4.3 PASSIVE APPROXIMATORS 79
  • 4.3.1 HEMOSTATIC PADS/PATCHES 82
  • 4.3.2 COMPRESSION DEVICES 84

5 VASCULAR CLOSURE DEVICES GLOBAL MARKET, BY INTERVENTION 86

• 5.1 INTRODUCTION 86
• 5.2 DIGNOSTICS 88
• 5.3 THERAPEUTICS 90

6 VASCULAR CLOSURE DEVICES GLOBAL MARKET, BY ACCESS 93

• 6.1 INTRODUCTION 93
• 6.2 FEMORAL ACCESS 95
• 6.3 RADIAL ACCESS 97

7 VASCULAR CLOSURE DEVICES GLOBAL MARKET, BY GEOGRAPHY 101

• 7.1 INTRODUCTION 101
• 7.2 NORTH AMERICA 102
• 7.3 EUROPE 108
• 7.4 ASIA PACIFIC 114
• 7.5 REST OF THE WORLD 119

8 COMPANY DEVELOPMENTS 126

• 8.1 INTRODUCTION 126
• 8.2 ACQUISITION AS A MAJOR GROWTH STRATEGY OF ACTIVE PHARMACEUTICAL INGREDIENTS MARKET PLAYERS 127
• 8.3 MERGERS AND ACQUISITION 127
• 8.4 AGREEMENTS PARTERNER SHIPS, COLLABORATIONS & JOINT VENTURES 131
• 8.5 APPROVALS 134
• 8.6 BUSINESS EXPANSION 137
• 8.7 NEW PRODUCT LAUNCH 139

9 COMPANY PROFILES 141

• 9.1 ABBOTT LABORATORIES 141
  • 9.1.1 OVERVIEW 141
  • 9.1.2 FINANCIALS 142
  • 9.1.3 PRODUCT PORTFOLIO 144
  • 9.1.4 KEY DEVELOPMENTS 145
  • 9.1.5 BUSINESS STRATEGY 146
  • 9.1.6 SWOT ANALYSIS 147
• 9.2 ADVANCED VASCULAR DYNAMICS 148
  • 9.2.1 OVERVIEW 148
  • 9.2.2 FINANCIALS 148
  • 9.2.3 PRODUCT PORTFOLIO 148
  • 9.2.4 KEY DEVELOPMENTS 149
  • 9.2.5 BUSINESS STRATEGY 149
  • 9.2.6 SWOT ANALYSIS 150
• 9.3 B. BRAUN MELSUNGEN AG 151
  • 9.3.1 OVERVIEW 151
  • 9.3.2 FINANCIALS 152
  • 9.3.3 PRODUCT PORTFOLIO 154
  • 9.3.4 KEY DEVELOPMENTS 155
  • 9.3.5 BUSINESS STRATEGY 156
  • 9.3.6 SWOT ANALYSIS 157
• 9.4 BIOTRONIK SE & CO. KG 158
  • 9.4.1 OVERVIEW 158
  • 9.4.2 FINANCIALS 158
  • 9.4.3 PRODUCT PORTFOLIO 158
  • 9.4.4 KEY DEVELOPMENTS 159
  • 9.4.5 BUSINESS STRATEGY 159
  • 9.4.6 SWOT ANALYSIS 160
• 9.5 C.R.BARD INC. 161
  • 9.5.1 OVERVIEW 161
  • 9.5.2 FINANCIALS 162
  • 9.5.3 PRODUCT PORTFOLIO 164
  • 9.5.4 KEY DEVELOPMENTS 165
  • 9.5.5 BUSINESS STRATEGY 166
  • 9.5.6 SWOT ANALYSIS 167
• 9.6 CARDINAL HEALTH INC. 168
  • 9.6.1 OVERVIEW 168
  • 9.6.2 FINANCIALS 169
  • 9.6.3 PRODUCT PORTFOLIO 171
  • 9.6.4 KEY DEVELOPMENTS 172
  • 9.6.5 BUSINESS STRATEGY 174
  • 9.6.6 SWOT ANALYSIS 175
• 9.7 CARDIVA MEDICALS, INC. 176
  • 9.7.1 OVERVIEW 176
  • 9.7.2 FINANCIALS 176
  • 9.7.3 PRODUCT PORTFOLIO 176
  • 9.7.4 KEY DEVELOPMENTS 177
  • 9.7.5 BUSINESS STRATEGY 177
  • 9.7.6 SWOT ANALYSIS 178
• 9.8 MORRIS INNOVATIVE, INC. 179
  • 9.8.1 OVERVIEW 179
  • 9.8.2 FINANCIALS 179
  • 9.8.3 PRODUCT PORTFOLIO 179
  • 9.8.4 KEY DEVELOPMENTS 180
  • 9.8.5 BUSINESS STRATEGY 180
  • 9.8.6 SWOT ANALYSIS 181
• 9.9 SCION BIOMEDICALS, INC. 182
  • 9.9.1 OVERVIEW 182
  • 9.9.2 FINANCIALS 182
  • 9.9.3 PRODUCT PORTFOLIO 182
  • 9.9.4 KEY DEVELOPMENTS 183
  • 9.9.5 BUSINESS STRATEGY 183
  • 9.9.6 SWOT ANALYSIS 184
• 9.10 ST.JUDE MEDICAL 185
  • 9.10.1 OVERVIEW 185
  • 9.10.2 FINANCIALS 186
  • 9.10.3 PRODUCT PORTFOLIO 188
  • 9.10.4 KEY DEVELOPMENTS 189
  • 9.10.5 BUSINESS STRATEGY 190
  • 9.10.6 SWOT ANALYSIS 191
• 9.11 TERUMO CORPORATION 192
  • 9.11.1 OVERVIEW 192
  • 9.11.2 FINANCIALS 193
  • 9.11.3 PRODUCT PORTFOLIO 195
  • 9.11.4 KEY DEVELOPMENTS 196
  • 9.11.5 BUSINESS STRATEGY 197
  • 9.11.6 SWOT ANALYSIS 199
• 9.12 VASCULAR SOLUTIONS INC. 200
  • 9.12.1 OVERVIEW 200
  • 9.12.2 FINANCIALS 200
  • 9.12.3 PRODUCT PORTFOLIO 202
  • 9.12.4 KEY DEVELOPMENTS 203
  • 9.12.5 BUSINESS STRATEGY 203
  • 9.12.6 SWOT ANALYSIS 204

LIST OF TABLES

TABLE 1 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 18

TABLE 2 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY TYPE,

(2014-2022) ($MN) 18

TABLE 3 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE,

BY INTERVENTION, (2014-2022) ($MN) 19

TABLE 4 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY ACCESS, (2014-2022) ($MN) 20

TABLE 5 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY TYPE,

(2014-2022) ($MN) 66

TABLE 6 ACTIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY REGION,

(2014-2022) ($MN) 69

TABLE 7 ACTIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY PRODUCT,

(2015-2022) ($MN) 70

TABLE 8 CLIPS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 71

TABLE 9 SUTURE MEDIATED DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 73

TABLE 10 PLUGS GLOBAL MARKET REVENUE, BY MATERIAL, (2014-2022) ($MN) 74

TABLE 11 PLUGS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 75

TABLE 12 COLLAGEN BASED PLUGS GLOBAL MARKET REVENUE, BY REGION,

(2014-2022) ($MN) 76

TABLE 13 POLYMER BASED PLUGS GLOBAL MARKET REVENUE, BY REGION,

(2014-2022) ($MN) 78

TABLE 14 PASSIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY PRODUCT,

(2014-2022) ($MN) 81

TABLE 15 PASSIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY REGION,

(2014-2022) ($MN) 82

TABLE 16 HEMOSTATIC PADS/PATCHES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 84

TABLE 17 COMPRESSION DEVICES GLOBAL MARKET REVENUE, BY REGION,

(2014-2022) ($MN) 85

TABLE 18 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE,

BY INTERVENTION, (2014-2022) ($MN) 88

TABLE 19 DIAGNOSTICS VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) 90

TABLE 20 THERAPEUTICS VASCULAR CLOSURE GLOBAL MARKET REVENUE,

BY REGION, (2014-2022) ($MN) 92

TABLE 21 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY ACCESS, (2014-2022) ($MN) 95

TABLE 22 FEMORAL VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE,

BY REGION, (2014-2022) ($MN) 97

TABLE 23 RADIAL VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE,

BY REGION, (2014-2022) ($MN) 100

TABLE 24 NORTH AMERICAN VASCULAR CLOSURE DEVICES MARKET REVENUE,

BY TYPE, (2014-2022) ($MN) 105

TABLE 25 NORTH AMERICAN ACTIVE APPROXIMATOR MARKET REVENUE,

BY PRODUCT, (2014-2022) ($MN) 105

TABLE 26 NORTH AMERICAN PLUGS MARKET REVENUE, BY MATERIAL,

(2014-2022) ($MN) 106

TABLE 27 NORTH AMERICAN PASSIVE APPROXIMATOR MARKET REVENUE,

BY PRODUCT, (2014-2022) ($MN) 106

TABLE 28 NORTH AMERICAN VASCULAR CLOSURE DEVICES MARKET REVENUE,

BY INTERVENTION, (2014-2022) ($MN) 107

TABLE 29 NORTH AMERICAN VASCULAR CLOSURE DEVICE MARKET REVENUE,

BY ACCESS, (2014-2022) ($MN) 107

TABLE 30 EUROPEAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 110

TABLE 31 EUROPEAN ACTIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN) 111

TABLE 32 EUROPEAN PLUGS MARKET REVENUE, BY MATERIAL, (2014-2022) ($MN) 111

TABLE 33 EUROPEAN PASSIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN) 112

TABLE 34 EUROPEAN VASCULAR CLOSURE DEVICES MARKET REVENUE,

BY INTERVENTION, (2014-2022) ($MN) 113

TABLE 35 EUROPEAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY ACCESS, (2014-2022) ($MN) 113

TABLE 36 ASIA-PACIFIC VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, (2014-2022) ($MN) 116

TABLE 37 ASIA-PACIFIC ACTIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN) 116

TABLE 38 ASIA-PACIFIC PLUGS MARKET REVENUE, BY MATERIAL, (2014-2022) ($MN) 117

TABLE 39 ASIA-PACIFIC PASSIVE APPROXIMATOR MARKET REVENUE, BY PRODCUT, (2014-2022) ($MN) 118

TABLE 40 ASIA-PACIFIC VASCULAR CLOSURE DEVICES MARKET REVENUE,

BY INTERVENTION, (2014-2022) ($MN) 118

TABLE 41 ASIA-PACIFIC VASCULAR CLOSURE DEVICES MARKET REVENUE,

BY ACCESS, (2014-2022) ($MN) 119

TABLE 42 ROW VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE,

(2014-2022) ($MN) 122

TABLE 43 ROW ACTIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT,

(2014-2022) ($MN) 123

TABLE 44 ROW PLUGS MARKET REVENUE, BY MATERIAL, (2014-2022) ($MN) 123

TABLE 45 ROW PASSIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT,

(2014-2022) ($MN) 124

TABLE 46 ROW VASCULAR CLOSURE DEVICES MARKET REVENUE, BY INTERVENTION, (2014-2022) ($MN) 124

TABLE 47 ROW VASCULAR CLOSURE DEVICES MARKET REVENUE, BY ACCESS,

(2014-2022) ($MN) 125

TABLE 48 MERGERS AND ACQUISITION (2011-2015) 128

TABLE 49 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES (2012-2015) 132

TABLE 50 APPROVALS (2011-2015) 135

TABLE 51 BUSINESS EXPANSION (2011-2015) 137

TABLE 52 NEW PRODUCT LAUNCH (2011-2015) 139

TABLE 53 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES,

(2013-2015) ($MN) 142

TABLE 54 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENT, (2013-2015) ($MN) 143

TABLE 55 ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN) 144

TABLE 56 B.BRAUN MELSUNGEN AG: TOTAL REVENUE AND R&D EXPENSES,

(2012-2014) ($MN) 152

TABLE 57 B.BRAUN MELSUNGEN AG: TOTAL REVENUE, BY SEGMENT,

(2012-2014) ($MN) 153

TABLE 58 B.BRAUN MELSUNGEN AG: TOTAL REVENUE, BY GEOGRAPHY,

(2012-2014) ($MN) 154

TABLE 59 C.R.BARD INC.: TOTAL REVENUE AND R&D EXPENSES (2013-2015) ($MN) 162

TABLE 60 C.R.BARD INC: TOTAL REVENUE, BY SEGMENT, (2013-15) ($MN) 163

TABLE 61 C.R.BARD INC: TOTAL REVENUE, BY REGION, (2013-15) ($MN) 164

TABLE 62 CARDINAL HEALTH, INC.: TOTAL REVENUE AND OPERATING EXPENSES, (2013-2015) ($MN) 169

TABLE 63 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENT,

(2013-2015) ($MN) 170

TABLE 64 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY,

(2013-2015) ($MN) 171

TABLE 65 ST JUDE MEDICAL: TOTAL REVENUE AND R&D EXPENSES,

(2013-2015) ($MN) 186

TABLE 66 ST JUDE MEDICAL : TOTAL REVENUE, BY SEGMENT, (2013-2015) ($MN) 187

TABLE 67 ST.JUDE INC.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN) 188

TABLE 68 TERUMO CORPORATION: TOTAL REVENUE AND R&D EXPENSES,

(2013-2015) ($MN) 193

TABLE 69 TERUMO CORPORATION: TOTAL REVENUE, BY SEGMENTS,

(2013-2015) ($MN) 194

TABLE 70 TERUMO CORPORATION: TOTAL REVENUE, BY GEOGRAPHY,

(2013-2015) ($MN) 195

TABLE 71 VASCULAR SOLUTIONS INC.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN) 200

TABLE 72 VASCULAR SOLUTIONS INC.: TOTAL REVENUE, BY SEGMENT,

(2013-2015) ($MN) 201

TABLE 73 VASCULAR SOLUTIONS INC.: TOTAL REVENUE, BY GEOGRAPHY,

(2013-2015) ($MN) 202

LIST OF FIGURES

FIGURE 1 VASCULAR CLOSURE DEVICE GLOBAL MARKET SHARE, BY GEOGRAPHY, (2014-22) ($MN) 17

FIGURE 2 RESEARCH METHODOLOGY: VASCULAR CLOSURE DEVICES MARKET 25

FIGURE 3 VASCULAR CLOSURE DEVICES MARKET: TOP-DOWN AND BOTTOM-UP APPROACH 26

FIGURE 4 VASCULAR CLOSURE DEVICES MARKET: FORECASTING MODEL 27

FIGURE 5 VASCULAR CLOSURE DEVICES MARKET: MARKET CRACHDOWN AND DATA TRIANGULATION 28

FIGURE 6 VASCULAR CLOSURE DEVICES MARKET: MARKET SEGMENTATION 34

FIGURE 7 MARKET DYNAMICS 36

FIGURE 8 VASCULAR CLOSURE DEVICES MARKET: PORTER’S ANALYSIS 43

FIGURE 9 VASCULAR CLOSURE DEVICE MARKET: SUPPLY CHAIN ANALYSIS 59

FIGURE 10 VASCULAR CLOSURE DEVICES GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2015 (%) 60

FIGURE 11 VASCULAR CLOSURE DEVICES MARKET: PATENT FILING BY MAJOR PLAYERS (2011-2015) 63

FIGURE 12 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY TYPE,

(2014-2022) ($MN) 65

FIGURE 13 ACTIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY PRODUCT, 2015, ($MN) 68

FIGURE 14 PASSIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY PRODUCT,

(2014-2022), ($MN) 80

FIGURE 15 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE,

BY INTERVENTION, (2014-22) ($MN) 87

FIGURE 16 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY ACCESS, (2015 V’S 2022) ($MN) 94

FIGURE 17 RADIAL ACCESS DEVICES GLOBAL MARKET SHARE, BY REGION, 2015, (%) 99

FIGURE 18 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) (CAGR %) 102

FIGURE 19 NORTH AMERICAN VASCULAR CLOSURE DEVICES MARKET REVENUE,

BY TYPE, INTERVENTION & ACCESS, (2015 V’S 2022) ($MN) 104

FIGURE 20 EUROPEAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, INTERVENTION & ACCESS, (2015 V’S 2022) ($MN) 109

FIGURE 21 ASIA-PACIFIC VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, INTERVENTION & ACCESS, (2015 V’S 2022) ($MN) 115

FIGURE 22 ROW VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, INTERVENTION & ACCESS, (2015 V’S 2022) ($MN) 121

FIGURE 23 KEY GROWTH STRATEGIES (2012-2015) 126

FIGURE 24 SWOT: ABBOTT LABORATORIES 147

FIGURE 25 SWOT: ADVANCED VASCULAR DYNAMICS 150

FIGURE 26 SWOT: B.BRAUN MELSUNGEN AG 157

FIGURE 27 SWOT: BIOTRONIK SE & CO. KG 160

FIGURE 28 SWOT: C.R.BARD INC. 167

FIGURE 29 SWOT: CARDINAL HEALTH, INC. 175

FIGURE 30 SWOT: CARDIVA MEDICALS, INC. 178

FIGURE 31 SWOT: MORRIS INNOVATIVE MEDICALS, CORP. 181

FIGURE 32 SWOT: SCION BIOMEDICAL, INC. 184

FIGURE 33 SWOT: ST.JUDE MEDICAL 191

FIGURE 34 SWOT: TERUMO CORPORATION 199

FIGURE 35 SWOT: VASCULAR SOLUTIONS INC. 204

Vascular closure is a procedure done for the closure of the punctured arterial wall after the performance of the catheterization procedure using the active and passive approximators. The active and passive approximators are the vascular closure device that reduce the blood loss with better haemostasis and reduce the time of ambulation with an increase the patient comfort. They are designed to provide quick and reliable haemostasis of access site after the invasive catheterization procedure. They were introduced in the 1990’s to overcome the complications caused by the manual compression. The vascular closure global market is valued at $XX million in 2015 and expected to grow at a high single digit CAGR to reach $1,665.2 million by 2022. The vascular closure devices global market is segmented by product type, access, intervention and geography.
Increasing catheterization related procedures (PCI), preference for minimally-invasive solutions & rise in vascular procedures, ease in usage and quick hemostatic properties of VCDs, and increased utilization of transradial arterial access are driving the growth of the market.
High price of products, complications associated with VCD, less adoption of novel technologies in emerging countries are hampering the market of vascular closure. Reduced reimbursement, usage of animal related sources and lower revenue potential of VCD are threats for the market growth.
The vascular closure device global market by products is segmented into active approximators and passive approximators. Active approximators are sub-segmented into clips, plugs and suture mediated device. Plugs are further divided into FISH, collagen based and polymer based plugs. Active approximators hold the largest share in 2015 and are growing at a CAGR of 7.5% and passive approximators is expected to grow at high single digit CAGR by 2022.
The vascular closure devices global market by intervention is mainly segmented into diagnostics and intervention. The diagnostic vascular closure devices global market hold the largest share in 2015 and expected to grow at a highest CAGR of 8.7% and therapeutic vascular closure devices segment is expected to grow at a CAGR of XX% by 2022.
The vascular closure global market by access is mainly segmented into femoral access and radial access. The femoral vascular closure devices global market hold the largest share in 2015 and expected to reach $XX million in 2022, at a CAGR of XX% and radial vascular access segment is also expected to grow at a highest CAGR to reach $340.9 by 2022.
The vascular closure devices global market by geography is divided into North America, Europe, Asia-Pacific and Rest of the world. North American region commanded the largest market share in 2015 and expected to reach $XX million by 2022, at high single digit CAGR due to increasing catheterization related procedures (PCI), preference for minimally-invasive solutions & rise in vascular procedures, ease in usage and quick hemostatic properties of VCDs and increased utilization of transradial arterial access. Europe region is expected to grow at a CAGR of XX% from 2015 to 2022 following the North American region.
Major players in the vascular closure market are Abbott Laboratories (U.S.), Advanced Vascular Dynamics (U.S.), B Braun Melsungen AG (Germany), Biotronik International (Germany), C R Bard (U.S.), Cardinal Health (U.S.), Cardiva Medical (U.S.), Morris Innovative (U.S.), Scion Biomedical (U.S.), St Jude Medical (U.S.), Terumo (Japan) and Vascular Solutions (U.S.).